Regulus filed a solicitation/recommendation statement on Schedule 14D-9 with the SEC, which includes, among other things, the recommendation of Regulus’s board of directors that Regulus’s stockholders ...

At Novartis, we innovate, develop and operate on a vast scale. You can be part of it. Join our creative community of professionals and you will find opportunities to make an unprecedented impact – on ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

V Novartisu spodbujamo inovativnost in razvoj ter delujemo na številnih področjih. Tudi vi lahko postanete del tega, del naše zgodbe. Pridružite se naši ustvarjalni skupnosti strokovnjakov in našli ...

Novartis is proud to share that CEO Vas Narasimhan, M.D., has been named to the 2025 TIME100 Health list—recognizing 100 of the most influential people driving the future of global health. Selected by ...

Syftet med studien är att utvärdera effekt och säkerhet av remibrutinib (LOU064) när det ges till patienter med skovvis förlöpande multipel skleros. Studiens huvudsyfte är att ta reda på om patienter ...

Fabhalta APPULSE-PNH full results build on Phase III program, reporting new data from expanded PNH population in adults switching from anti-C5 Ianalumab Phase II data in immune thrombocytopenia and ...

Novartis is committed to working with and providing reasonable accommodation to individuals with disabilities. If, because of a medical condition or disability, you need a reasonable accommodation for ...

2025年4月29日、スイス・バーゼル発 ― ノバルティスCEOのヴァス･ナラシンハンは、2025年第1四半期の業績について、次のようにコメントしています。 「ノバルティスは、2025年第1四半期の ...

Why Novartis: Helping people with disease and their families takes more than innovative science. It takes a community of smart, passionate people like you. Collaborating, supporting and inspiring each ...

• Applications are now being accepted, with $500,000 in grants to be awarded to projects focused on improving health equity in Canada Montreal, Quebec, May 14, 2025 – Novartis Pharmaceuticals Canada ...

While the exact reason for this gender imbalance remains unknown, researchers are exploring contributing factors, including hormones, environmental triggers, and antibody levels. 3 Nevertheless, the ...